mhurhangee/ep-ind-claims huggingface dataset:
A pharmaceutical composition comprising a compound of formula (I-a): or a pharmaceutically acceptable salt, solvate, or hydrate thereof, wherein: R 1, R 2, R 3, R 4, R 6a, and R 6b are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, heterocyclyl, aryl, -OR A, -OC R A, -SR A, -N(R B) 2, -N(R A)C R A,-C N(R B) 2, -CN, -NO 2, -C R A, -C OR A, -S R A, -SO 2 R A, -SO 2 (R B) 2, and -NHSO 2 R B; one of R 1, R 2, R 3, and R 4 is of the formula: wherein R 12 and R 13 are independently selected from hydrogen, -CO 2 H, -C OR A,-C N(R B) 2, -OH, -NO 2, -CN, halogen, alkyl, aryl and heterocyclyl, or R 12 and R 13 are taken together with their intervening atoms to form a carbocycle or heterocycle; R 14 is selected from hydrogen, -CO 2 H, -C OR A, -C N(R B) 2, -OH, -NO 2, -CN, halogen, alkyl, aryl and heterocyclyl. each instance of R 5 is independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, heterocyclyl, aryl, -OR A, -OC R A, -SR A, -N(R B) 2, -N(R A)C R A, -C N(R B) 2,-CN, -NO 2, -C R A, -C OR A, -S R A, -SO 2 R A, -SO 2 N(R B) 2, and -NHSO 2 R B; each R A is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heterocyclyl, and aryl; each R B is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heterocyclyl, and aryl, or two R B taken together with the intervening nitrogen form a heterocycle; n is 0, 1, 2, 3, or 4; and a pharmaceutically acceptable excipient. R 1, R 2, R 3, R 4, R 6a, and R 6b are each independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, heterocyclyl, aryl, -OR A, -OC R A, -SR A, -N(R B) 2, -N(R A)C R A,-C N(R B) 2, -CN, -NO 2, -C R A, -C OR A, -S R A, -SO 2 R A, -SO 2 (R B) 2, and -NHSO 2 R B; one of R 1, R 2, R 3, and R 4 is of the formula: wherein R 12 and R 13 are independently selected from hydrogen, -CO 2 H, -C OR A,-C N(R B) 2, -OH, -NO 2, -CN, halogen, alkyl, aryl and heterocyclyl, or R 12 and R 13 are taken together with their intervening atoms to form a carbocycle or heterocycle; R 14 is selected from hydrogen, -CO 2 H, -C OR A, -C N(R B) 2, -OH, -NO 2, -CN, halogen, alkyl, aryl and heterocyclyl. each instance of R 5 is independently selected from hydrogen, halogen, alkyl, alkenyl, alkynyl, heterocyclyl, aryl, -OR A, -OC R A, -SR A, -N(R B) 2, -N(R A)C R A, -C N(R B) 2,-CN, -NO 2, -C R A, -C OR A, -S R A, -SO 2 R A, -SO 2 N(R B) 2, and -NHSO 2 R B; each R A is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heterocyclyl, and aryl; each R B is independently selected from hydrogen, alkyl, alkenyl, alkynyl, heterocyclyl, and aryl, or two R B taken together with the intervening nitrogen form a heterocycle; n is 0, 1, 2, 3, or 4; and
A packaging unit for substrates (1, 1'), comprising: - a first substrate, - a spacer, and - a second substrate, wherein the spacer is placed onto the first substrate and the second substrate is placed onto the spacer, wherein a metal depot (2, 2') is disposed onto a surface of the first substrate as well as onto a surface of the second substrate and an adhesion point (3, 3') is disposed on both metal depots (2, 2'), and wherein the spacer is placed onto the first substrate such that the spacer touches the first substrate only outside the adhesion point, wherein the spacer is strut-shaped, and wherein at least the first substrate comprises a plurality of individual substrates disposed adjacently and the spacer borders the individual substrates. - a first substrate, - a spacer, and - a second substrate,
A rubber composition comprising at least a surfactant comprising a thioether functionality and one or more antidegradants; wherein the rubber is selected from the group consisting of natural rubber, polyisoprene rubber, styrene butadience rubber, polybutadiene rubber, butyl rubber, halobutyl rubber, crosslinked polyethylene rubber, neoprenes, chlorinated polyethylene rubbers, silicone rubbers, and mixtures thereof.
A method for providing a diagnosis of acute kidney injury in a subject displaying symptoms of AKI, the method comprising: passing a vesicle containing biological sample obtained from said subject through a vesicle-capture material, thereby generating a vesicle sample; performing a nucleic acid-based detection assay to detect mRNA expression level of at least two genes in said vesicle sample, wherein each of said at least two genes is selected from the group consisting of CALB1, CALM1, CFLAR, EGF, GSTA1, HIF1A, IL18, PKM, PPIA, RIPK1, and SLC12A1; comparing said mRNA expression level of said at least two genes of the subject to that of a pre-determined standard to determine a level of over-expression or under-expression of said at least two genes in said subject relative to the standard; and determining the AKI severity in the subject, wherein the level of over-expression or under-expression of said at least two genes indicates the AKI severity in the subject, wherein said determining further involves generating a gene classifier expressed as a summation of the expression levels of said at least two genes; and determining that said subject has said AKI due to a summation of said expression levels of said at least two genes contained in the gene classifier being significantly different from a summation of said expression levels of corresponding genes in a vesicle sample obtained from a healthy human control subject not suffering from said AKI. passing a vesicle containing biological sample obtained from said subject through a vesicle-capture material, thereby generating a vesicle sample; performing a nucleic acid-based detection assay to detect mRNA expression level of at least two genes in said vesicle sample, wherein each of said at least two genes is selected from the group consisting of CALB1, CALM1, CFLAR, EGF, GSTA1, HIF1A, IL18, PKM, PPIA, RIPK1, and SLC12A1; comparing said mRNA expression level of said at least two genes of the subject to that of a pre-determined standard to determine a level of over-expression or under-expression of said at least two genes in said subject relative to the standard; and determining the AKI severity in the subject, wherein the level of over-expression or under-expression of said at least two genes indicates the AKI severity in the subject, wherein said determining further involves generating a gene classifier expressed as a summation of the expression levels of said at least two genes; and determining that said subject has said AKI due to a summation of said expression levels of said at least two genes contained in the gene classifier being significantly different from a summation of said expression levels of corresponding genes in a vesicle sample obtained from a healthy human control subject not suffering from said AKI.
A composition of hair oil for stimulation of hair growth, control hair fall, dandruff and infections thereof, comprising following active ingredients: Capric Caprylic Tri-Glycerides (CCTG); mineral oil; coconut oil; ylang ylang oil; di-propylene glycol; centella asiatica extract; and butylated hydroxytoluene. Capric Caprylic Tri-Glycerides (CCTG); mineral oil; coconut oil; ylang ylang oil; di-propylene glycol; centella asiatica extract; and butylated hydroxytoluene.
A side-emitting optical waveguide, comprising a core with at least one inner core extending therein, and a transparent cladding surrounding the core, wherein said core and said cladding are formed from transparent plastics material, with the core having a higher refractive index than the cladding, and with the inner core being adapted to deflect light, in particular to reflect or scatter light, in order to scatter light that is carried in the optical waveguide and to emit it to the outside through the cladding; characterized in that the scattering length of the inner core is at most twice the maximum cross dimension of the inner core, the scattering length being defined as the length at which, due to the scattering, the initial intensity of the light in the direction of irradiation has dropped to a factor of 1/e; and wherein the inner core comprises light-scattering elements and extends centrally through the core, so that the light-scattering elements of the inner core are arranged in a concentrated fashion in a discrete area within the core at least partially or in sections thereof.
A package containing a plurality of petri dishes with nutrient media contained therein for prolonged shelf life and preservation thereof, said package comprising an optically clear, high-barrier, moisture-, gas- and microbial-resistant pouch, said pouch having an interior cavity and containing a plurality of sterile nutrient media-containing petri dishes immobilized therein, wherein the pouch is heat-sealed after having air being evacuated from the interior cavity of the pouch, and wherein the clarity of the pouch, immobility, alignment and cushioning of the petri dishes therein, and the evacuation of air, allow for prolonged shelf life and preservation of sterility of the petri dishes and the nutrient media contained therein, substantially no breakage of the petri dishes, and enhanced visibility of each of the petri dishes by a user, characterized in that the package is flat and each of said plurality of petri dishes is located adjacent one another aligned substantially in a coplanar arrangement within the interior cavity of the pouch.
A method of preparation of metaxalone having the following structural formula: comprising reaction of triglycidyl isocyanurate (TGIC) of formula with m-xylenol of formula characterized in that said reaction is carried out in a solvent mixture comprising a first solvent selected from the group consisting of N-methylpyrrolidone, dimethylformamide, dimethylsulphoxide, hexamethylphosphoramide, dimethylacetamide and acetonitrile and a second solvent selected from the group consisting of cyclohexane, heptane, benzene, toluene, xylene, mesitylene, naphthalene, chlorobenzene, chloroxylene, chloroform, propyl ether, isopropyl ether, butyl ether, pentyl ether, benzylethyl ether, tetrahydrofuran, 2-methyl tetrahydrofuran, acetone, methyl ethyl ketone, methyl butyl ketone, methyl isobutyl ketone, 2-pentanone, cyclopentanone and 2-heptanone, said solvent mixture comprising from 5 to 40 wt. % of said first solvent and from 95 to 60 wt. % of said second solvent, adding the TGIC at a temperature between 30°C and 50°C and after adding the TGIC raising the temperature of the reaction solution to a value between 80°C and 180°C in a time between 120 and 180 minutes at a rate of increase not greater that 1.25 °C per minute.
CD2 Polypeptide for use in a method of reducing pathological angiogenesis in an individual, the method comprising: administering to an individual an effective dose of a variant of human or mouse domain one of the polypeptide, wherein the administration provides for reduction of pathological angiogenesis in the individual, and wherein the polypeptide is selected from the group consisting of Sequence Id. No. 1, Sequence Id. No. 2, Sequence Id. No. 3, Sequence Id. No. 4, Sequence Id. No. 5, Sequence Id. No. 6, Sequence Id. No. 7, Sequence Id. No. 8, Sequence Id. No. 9, Sequence Id. No. 10, and Sequence Id. No. 11.
An electrode catheter (100, 200) comprising: a catheter shaft (10, 60) that has at least one lumen (12L, 61L, 62L, 63L, 64L); at least one ring-shaped electrode (201, 202, 203, 204, 205, 206, 207, 208, 209, 210; 72, 73, 74) that is attached to an outer circumferential surface of a distal end part (101, 601) of the catheter shaft (10, 60); and a lead (301, 302, 303, 304, 305, 306, 307, 308, 309, 310; 82, 83, 84) that is coupled to the ring-shaped electrode (201, 202, 203, 204, 205, 206, 207, 208, 209, 210; 72, 73, 74), wherein a side hole that extends from the outer circumferential surface to the lumen is formed in a tube wall of the distal end part (101, 601) of the catheter shaft (10, 60) in correspondence to an attachment position of the ring-shaped electrode (201, 202, 203, 204, 205, 206, 207, 208, 209, 210,72, 73, 74), wherein the lead (301, 302, 303, 304, 305, 306, 307, 308, 309, 310; 82, 83, 84) is configured by coating a metal core wire with a resin, the lead (301, 302, 303, 304, 305, 306, 307, 308, 309, 310; 82, 83, 84) being joined at a distal end portion thereof to an inner circumferential surface of the ring-shaped electrode (201, 202, 203, 204, 205, 206, 207, 208, 209, 210,72, 73, 74) and thereby being coupled to said ring-shaped electrode (201, 202, 203, 204, 205, 206, 207, 208, 209, 210,72, 73, 74) while entering the lumen through the side hole and extending in said lumen, and wherein the catheter shaft (10, 60) is constituted by a braided tube that is reinforced by a braid (135, 65) made of a resin throughout the entire length thereof. a catheter shaft (10, 60) that has at least one lumen (12L, 61L, 62L, 63L, 64L); at least one ring-shaped electrode (201, 202, 203, 204, 205, 206, 207, 208, 209, 210; 72, 73, 74) that is attached to an outer circumferential surface of a distal end part (101, 601) of the catheter shaft (10, 60); and a lead (301, 302, 303, 304, 305, 306, 307, 308, 309, 310; 82, 83, 84) that is coupled to the ring-shaped electrode (201, 202, 203, 204, 205, 206, 207, 208, 209, 210; 72, 73, 74), wherein a side hole that extends from the outer circumferential surface to the lumen is formed in a tube wall of the distal end part (101, 601) of the catheter shaft (10, 60) in correspondence to an attachment position of the ring-shaped electrode (201, 202, 203, 204, 205, 206, 207, 208, 209, 210,72, 73, 74), wherein the lead (301, 302, 303, 304, 305, 306, 307, 308, 309, 310; 82, 83, 84) is configured by coating a metal core wire with a resin, the lead (301, 302, 303, 304, 305, 306, 307, 308, 309, 310; 82, 83, 84) being joined at a distal end portion thereof to an inner circumferential surface of the ring-shaped electrode (201, 202, 203, 204, 205, 206, 207, 208, 209, 210,72, 73, 74) and thereby being coupled to said ring-shaped electrode (201, 202, 203, 204, 205, 206, 207, 208, 209, 210,72, 73, 74) while entering the lumen through the side hole and extending in said lumen, and wherein the catheter shaft (10, 60) is constituted by a braided tube that is reinforced by a braid (135, 65) made of a resin throughout the entire length thereof.
A method performed by a terminal (110, 210, 310) in a wireless communication system, the method comprising: receiving, from a base station (120, 220, 320), downlink signals for transmission beams; and transmitting, to the base station (120, 220, 320), measurement information including best beam information and other beam information, based on the downlink signals, wherein the best beam information indicates a first transmission beam corresponding to a best channel quality among the transmission beams, wherein the other beam information indicates at least one second transmission beam other than the first transmission beam among the transmission beams, wherein a channel quality of each beam of the at least one second transmission beam is greater than a threshold, and wherein a broadcast message including information for identifying the other beam information is received from the base station (120, 220, 320). receiving, from a base station (120, 220, 320), downlink signals for transmission beams; and transmitting, to the base station (120, 220, 320), measurement information including best beam information and other beam information, based on the downlink signals, wherein the best beam information indicates a first transmission beam corresponding to a best channel quality among the transmission beams, wherein the other beam information indicates at least one second transmission beam other than the first transmission beam among the transmission beams, wherein a channel quality of each beam of the at least one second transmission beam is greater than a threshold, and wherein a broadcast message including information for identifying the other beam information is received from the base station (120, 220, 320).
A nucleotide sequence comprising a single open reading frame encoding parvoviral Rep78 and Rep52 proteins, wherein the initiation codon for translation of the parvoviral Rep78 protein is a suboptimal initiation codon as compared to the normal ATG codon, wherein the nucleotide sequence comprises an expression control sequence comprising a nine nucleotide sequence of SEQ. ID NO: 7 upstream of the initiation codon of the nucleotide sequence encoding the parvoviral Rep78 protein.
A process for making a building structure, the process comprising the steps of: a) providing a housing which is open at the top; b) mounting a skeleton within said housing; c) pouring a lightweight conglomerate into said housing so as to bury said skeleton; d) letting said lightweight conglomerate harden; characterized in that said lightweight conglomerate is obtained by mixing water with an aggregate comprising: a) a granular mineral inert material comprising at least one component from the group consisting of: • expanded perlite, • expanded vermiculite, • pumice, • clay; b) a binder comprising hydraulic lime; c) vegetable fibres comprising hygroscopic material; and in that the material of at least some parts of said skeleton is wood; said aggregate having the following composition in weight: • from 25.5 % to 34.5 % of said mineral inert material; • from 42.5 % to 57.5 % of said binder; • from 8.5 % to 11.5 % of said vegetable fibres; • from 8.5 % to 11.5 % of additives. a) providing a housing which is open at the top; b) mounting a skeleton within said housing; c) pouring a lightweight conglomerate into said housing so as to bury said skeleton; d) letting said lightweight conglomerate harden; a) a granular mineral inert material comprising at least one component from the group consisting of: • expanded perlite, • expanded vermiculite, • pumice, • clay; • expanded perlite, • expanded vermiculite, • pumice, • clay; b) a binder comprising hydraulic lime; c) vegetable fibres comprising hygroscopic material; • from 25.5 % to 34.5 % of said mineral inert material; • from 42.5 % to 57.5 % of said binder; • from 8.5 % to 11.5 % of said vegetable fibres; • from 8.5 % to 11.5 % of additives.
A temperature controlled therapy system, comprising: a reservoir comprising an interior defined by a floor and at least one wall; an outlet in the reservoir; a therapy wrap having an inlet and an outlet; a pump having an inlet in communication with the reservoir outlet and an outlet in communication with the therapy wrap inlet; characterised by a diverter valve in communication with the therapy wrap outlet; a first inlet in the reservoir in communication with the diverter valve and positioned to direct flow from the first inlet into the reservoir; and a second inlet in the reservoir in communication with the diverter valve. a reservoir comprising an interior defined by a floor and at least one wall; an outlet in the reservoir; a therapy wrap having an inlet and an outlet; a pump having an inlet in communication with the reservoir outlet and an outlet in communication with the therapy wrap inlet; characterised by a diverter valve in communication with the therapy wrap outlet; a first inlet in the reservoir in communication with the diverter valve and positioned to direct flow from the first inlet into the reservoir; and a second inlet in the reservoir in communication with the diverter valve.
A resin composition consisting essentially of an ethylene-vinylalcohol copolymer and a hydroxyl group containing compound, the hydroxyl group containing compound having a molecular weight of 200 or less, a ratio of a number of hydroxyl groups in one molecule relative to the molecular weight within a range of 0.02-0.03, and a melting point of 23°C or higher and 200°C or lower, measured with a method in conformity with JIS K0064, a content of the hydroxyl group containing compound being 3-15 mass% relative to the resin composition, and wherein the ethylene-vinylalcohol copolymer has an ethylene content in a range of 20-60 mol%.
A power control circuitry for controlling a radio frequency, RF, transmitter (101, 103, 105) of a network equipment or a user equipment, the power control circuitry comprising: a controller configured to control a power level of an RF signal generated by the RF transmitter (101, 103, 105) for transmission via an antenna arrangement (102, 104, 106), wherein the power level is controlled based on information about an object within a coverage area of the antenna arrangement (102, 104, 106), wherein the RF signal is partitioned in a plurality of radio frames (311, 312, 313) and the controller is configured to reduce the power level of the RF signal based on suppressing transmission of a subset of the radio frames (311, 312, 313) of the RF signal and to coordinate with at least one other RF transmitter (101, 103, 105) which of the radio frames (311, 312, 313) of the RF signal to transmit by the RF transmitter (101, 103, 105).
A method of producing bioethanol by separating lignin from a comminuted lignocellulosic biomass, wherein the comminuted lignocellulosic biomass is treated with an alkanolamine that is not substituted by alkyl groups on the nitrogen atom, the lignin is extracted and the lignin solution separated, and the cellulose-/hemicellulose-containing residue obtained is converted to sugars without drying and the sugars are fermented to obtain bioethanol, characterised in that the comminuted lignocellulosic biomass is treated with the alkanolamine to extract the lignin contained therein, a treatment of the lignocellulosic biomass with a solution of ammonia in ethanolamine taking place prior to the extraction.
A heat shield for a turbocharger, the heat shield having a disc-like configuration defining a central bore and comprising: an outer radial portion disposed circumferentially around an axis of the heat shield; and an inner wall (214, 214', 214") extending from the connecting wall (212, 212', 212") in a second axial direction opposite the first axial direction; characterized in that an outer wall (210, 210', 210") extends from the outer radial portion in a first axial direction; a connecting wall (212, 212', 212") extends radially inward from the outer wall (210, 210', 210"); and in that the connecting wall (212, 212', 212") extends substantially perpendicularly from the outer wall (210, 210', 210") and the inner wall (214, 214', 214") extends substantially perpendicularly from the connecting wall (212, 212', 212"). an outer radial portion disposed circumferentially around an axis of the heat shield; and an inner wall (214, 214', 214") extending from the connecting wall (212, 212', 212") in a second axial direction opposite the first axial direction; characterized in that an outer wall (210, 210', 210") extends from the outer radial portion in a first axial direction; a connecting wall (212, 212', 212") extends radially inward from the outer wall (210, 210', 210"); and in that the connecting wall (212, 212', 212") extends substantially perpendicularly from the outer wall (210, 210', 210") and the inner wall (214, 214', 214") extends substantially perpendicularly from the connecting wall (212, 212', 212").